Site specific responses to immune checkpoint inhibitors
Immuno-Oncology Insights 2022; 3(5), 319–329
Immune checkpoint inhibitors are now part of the therapy of many solid tumor cancers. While many organ sites have multiple histologic subtypes of cancer, the objective response rate to these agents in a given site is not clear. We examine 62 clinical trials with at least one single agent immune checkpoint inhibitors arm to determine how various histologic subtypes in a given site respond. We show that histologic subtype of cancer does not affect objective response rate at a given site and that there appears to be a set point for each organ site.